The Oxford-Astrazeneca vaccine may be available in the country during the first half of next year to prevent Covid infection. The head of Oxford-Astrazeneca in India, Gagandeep Singh, gave this information on Saturday. At the 93rd annual FICCI conference, he said that in the current state of the epidemic, the vaccine will be available on a broader scale and in due course. Singh said: “We started working with the University of Oxford in April and we currently expect emergency use of this vaccine. This means that the vaccine could be available in the first half of 2021.”
The Oxford vaccine favors India: The Oxford-Astrazeneca vaccine has been found to be a much better option than the Moderna, Pfizer, or Sputnik-V vaccine. However, the scientists note that the disclosed data is still in the early stage. It will be 70% effective on average. The vaccine produced in collaboration with the University of Oxford was found to be 70.4 percent effective in the third stage trial. After the 2 doses of vaccine were administered to the participants, the data disclosed was mixed and the result was found to be positive. However, the effect of the vaccine in two different doses was 90% in one and 62% in the other.
The scientists also warned: It is also said that based on the data, many scientists have said they should be cautious with optimism about Oxford-AstraZeneca. He said it is also important to remember that his figures are temporary and it is still difficult to make a full analysis of them. According to the information received, Andrew Pollard, director of the ‘Oxford Vaccine Group’ and chief investigator of the ‘Oxford Vaccine Trial’, said: “The results show that we have an effective vaccine that protects many lives. Encouragingly, we found Is it that one of our doses can be approximately 90 percent effective. “
The Oxford-Astrazeneca vaccine may be available in the country during the first half of next year to prevent Covid infection. The head of Oxford-Astrazeneca in India, Gagandeep Singh, gave this information on Saturday. At the 93rd annual FICCI conference, he said that in the current state of the epidemic, the vaccine will be available on a wider scale and in due course. Singh said: “We started working with the University of Oxford in April and we are currently expecting the emergency use of this vaccine. This means that the vaccine could be available in the first half of 2021.”
The Oxford vaccine favors India: The Oxford-Astrazeneca vaccine has been found to be a much better option than the Moderna, Pfizer, or Sputnik-V vaccine. However, the scientists note that the disclosed data is still in the early stage. It will be 70% effective on average. The vaccine produced in collaboration with the University of Oxford was found to be 70.4 percent effective in the third stage trial. After the 2 doses of vaccine were administered to the participants, the data disclosed was mixed and the result was positive. However, the effect of the vaccine in two different doses was 90% in one and 62% in the other.
The scientists also warned: It is also said that based on the data, many scientists have said they should be cautious with optimism about Oxford-AstraZeneca. He said it is also important to remember that their figures are temporary and it is still difficult to make a full analysis of them. According to the information received, Andrew Pollard, director of the ‘Oxford Vaccine Group’ and chief investigator of the ‘Oxford Vaccine Trial’, said: “The results show that we have an effective vaccine that protects many lives. It is encouraging that we found one of our doses can be about 90 percent effective. “
Read also: –
Source